Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Expands ADC Pipeline With Option Agreement for CPT113 Linker-Payload

Neutral Impact 3 of 5 product/contract Written later

Whitehawk Therapeutics entered an option agreement with Hangzhou DAC Biotechnology for access to the CPT113 linker-payload for use in up to five additional antibody drug conjugate (ADC) programs. The filing does not disclose financial terms, and the company said Hangzhou DAC's DXC006, which uses CPT113, will present data at ASCO.

Key points

  • Option agreement gives Whitehawk access to CPT113 for up to five additional ADC programs; the filing gives no financial terms.
  • Whitehawk expects to submit IND applications for multiple new programs over the next 12-24 months.
  • Hangzhou DAC's DXC006 data were accepted for oral presentation at ASCO; the company's HWK-007 trial-in-progress poster is scheduled for May 30, 2026.
  • Phase 1 data for HWK-007 and HWK-016 are expected in the first half of 2027.

The filing

CompanyWhitehawk Therapeutics, Inc. (WHWK)
Form8-K, current report
Filed with the SECMay 21, 2026, 5:16 PM ET
Accession number0001193125-26-234890

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.